On July 14, 2015, the fifth subject was treated in our ongoing Israeli study of MDMA-assisted psychotherapy for PTSD. The seventh subject was enrolled on July 23. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat up to 10 subjects with chronic, treatment-resistant PTSD from any cause. “The entire clinical research team is pleased with the recent progress of our Israeli study, with four subjects enrolled in the last month,” reports MAPS Clinical Research Scientist Berra Yazar-Klosinski, Ph.D. This study is actively seeking Israeli participants.
